ACQUISITIONS AND DIVESTITURES (Tables)

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

Schedule of Business Acquisitions, by Acquisition

The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:

(In thousands)
Cash	$	52,527
Fair value of replaced equity awards	1,675
Total purchase price	$	54,202

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values as follows:

(In thousands)
Net operating assets	$	14,663
Developed technology	26,000
Total identifiable assets acquired	40,663
Net operating liabilities	(7,029)
Net identifiable assets acquired	33,634
Goodwill	20,568
Net assets acquired	$	54,202

Business Acquisition, Pro Forma Information

The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2023		2022		2023		2022
Total revenues	$	629,857	$	525,802	$	1,859,353	$	1,541,154
Net loss before tax	(7,257)		(163,261)		(181,660)		(535,017)